EBT Medical

EBT Medical operates in the specialized pelvic-health neuromodulation segment rather than competing broadly across medical devices. Its lead product, NiNA, is described as a non-invasive neurostimulator and disease-management system targeting overactive bladder through stimulation of the saphenous nerve. That focus differentiates the company from medication-centered treatment approaches and from more invasive surgical or implantable therapies, although the commercial and regulatory position of NiNA is not fully disclosed. The company’s 27 granted patents and additional patent activity around wearable therapy, pudendal nerve stimulation, and targeted lower-limb nerve stimulation indicate an emphasis on proprietary treatment protocols and delivery systems. EBT’s competitive profile is best characterized as an early-stage, clinically oriented medical-device developer addressing an underserved urology market, with differentiation centered on non-invasive stimulation, disease management, and pelvic-health specialization.

EBT Medical was founded in 2014 from scientific discoveries at the University of Toronto and has progressed from university-originated research toward a clinical-stage pelvic-health device company. It raised a $100,000 grant on Oct 17, 2018 and a $10 million Series A on Nov 19, 2019, bringing disclosed funding to $10.1 million across two rounds. The company’s latest structured financing history ends in 2019, but a 2026 announcement involving NinaMED described a separate US$13.75 million financing to advance the licensed NiNA System®; the relationship between that financing and EBT’s historical total is not fully clear, so it is not added to the funding total. Product and intellectual-property development has broadened from targeted nerve stimulation for incontinence and pelvic-floor disorders to wearable neurostimulation with curated therapy, with patent publications in 2023, 2024, and 2025. The 2026 board appointment of Ivan Jarry suggests a focus on commercialization and international scaling, while limited hiring and revenue information makes headcount or operating-growth assessment uncertain.